Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Here are some of the recent management changes that took place during the week: Biogen (NASDAQ:BIIB) said its Executive Vice ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB.

Needham analyst Ami Fadia has maintained their bullish stance on BIIB stock, giving a Buy rating yesterday. Ami Fadia has given her Buy rating ...

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Sage (SAGE) stock fell 18% post-market after the company released its Q3 earnings report and said it was ending development ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Ballentine Partners LLC lowered its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 54.1% in the 3rd quarter, according ...

On Monday, Biogen Inc (BIIB) stock saw a decline, ending the day at $184.65 which represents a decrease of $-5.51 or -2.90% from the prior close of $190.16. The stock opened at $190.16 and touched a ...